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Thrombolysis remains the only approved therapy for acute 
ischaemic stroke (AIS); however, its utilisation is reported to 
be low. 
Aims 
This study aimed to determine the reasons for the low 
utilisation of thrombolysis in clinical practice. 
Method   
Five metropolitan hospitals comprising two tertiary referral 
centres and three district hospitals conducted a 
retrospective, cross-sectional study. Researchers identified 
patients discharged with a principal diagnosis of AIS over a 
12-month time period (July 2009–July 2010), and reviewed 
the medical record of systematically chosen samples. 
Results 
The research team reviewed a total of 521 records (48.8% 
females, mean age 74.4 ±14 years, age range 5-102 years) 
from the 1261 AIS patients. Sixty-nine per cent of AIS 
patients failed to meet eligibility criteria to receive 
thrombolysis because individuals arrived at the hospital 
later than 4.5 hours after the onset of symptoms. The 
factors found to be positively associated with late arrival 
included confusion at onset, absence of a witness at onset 
and waiting for improvement of symptoms. However, 
factors negatively associated with late arrival encompassed 
facial droop, slurred speech and immediately calling an 
ambulance. Only 14.7% of the patients arriving within 4.5 
hours received thrombolysis. The main reasons for exclusion 
included such factors as rapidly improving symptoms 
(28.2%), minor symptoms (17.2%), patient receiving 
therapeutic anticoagulation (6.7%) and severe stroke 
(5.5%). 
Conclusion 
A late patient presentation represents the most significant 
barrier to utilising thrombolysis in the acute stroke setting. 
Thrombolysis continues to be currently underutilised in 
potentially eligible patients, and additional research is 
needed to identify more precise criteria for selecting 
patients for thrombolysis. 
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What this study adds: 
Thrombolysis constitutes the only approved therapy for 
acute ischaemic stroke. However, reports indicate its 
utilisation remains consistently low. This study identified 
the factors associated with the underutilisation of 
thrombolysis. Late patient presentation creates the most 
significant barrier to utilising thrombolysis in the acute 
stroke setting. Thrombolysis continues to be currently 
underutilised in potentially eligible patients, and additional 
research needs to identify more precise criteria for selecting 
patients for thrombolysis. 
 
Background 
In Australia, acute ischaemic stroke (AIS) treatment used 
thrombolysis with recombinant tissue plasminogen 
activator (rPA) starting about a decade ago.
1
 The national 
and international stroke management guidelines
2-4 
recommend thrombolysis in the treatment of AIS based on 
the superior level of evidence for its safety and 
effectiveness.
5-6
 The recently reported International Stroke 
Trial 3 (IST-3) affirms the benefit for tPA delivered within 
three hours from stroke onset, also supports the use of tPA 
in patients over age 80 and in patients with more severe 
stroke.
7
 However, the current utilisation of thrombolysis in 
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everyday clinical practice remains low.
8
 The literature points 
out several factors associated with the low frequency of 
utilisation. The presentation of stroke patients at hospitals 
beyond the narrow time window for safe and effective 
administration (4.5 hours) represents the most common 
reason for non-use of thrombolysis.
2,9
 Even among patients 
arriving within the time window, rates of thrombolysis 
utilisation continue to be low suggesting other significant 
barriers to thrombolysis exist.
8,10
  Several interventions may 
overcome these barriers such as public awareness 
campaigns,
11,12
 pre-hospital triage by paramedics, hospital 
bypass protocols coupled with pre-notification systems
13
 
and urgent neuroimaging protocols.
14
 These published 
interventions demonstrated success, however their impact 
on the national and global thrombolysis utilisation rates 
shows limited utilisation, revealed by the fact that only a 
small number of stroke treating centres use the published 
interventions.  
 
This study primarily aims to further explore reasons for the 
low rates of utilisation of thrombolysis in clinical practice in 
the Australian setting. The specific objectives plan to 
identify and quantify the reasons for patients presenting 
within the time window and not receiving thrombolysis, and 
to document factors associated with patients’ presenting 




The study design encompassed a retrospective, cross-
sectional study of AIS patients presenting over a one-year 
period from July 2009 to July 2010 to any of the study 
hospitals. The study included five metropolitan hospitals in 
total, two tertiary referral centres (TRC) and three district 
hospitals (DH) with varying characteristics as outlined in 
Table 1. This sampling strategy aimed to capture a 
representative sample of ischaemic stroke patients 
presenting to public hospitals at different geographic 
locations across NSW. The International Classification of 
Diseases (tenth revision) codes for AIS (I63.x, I64)
15
 assisted 
in identification of records for detailed review. To cover the 
entire study period, the researchers used a systematic 
sampling technique (i.e., starting with the first record and 
then selecting every n
th
 record from a patient list ordered by 
admission date). Due to varying admission numbers at each 
hospital every second record was reviewed at TRC-1 and 
DH-2, every third record was reviewed at TRC-2, every 
fourth record was reviewed at DH-3 while all the records 
were reviewed at DH-1. 
Data collection 
A thorough assessment of medical records, ambulance 
transfer sheets and electronic health information databases 
encompassed the review process. The extracted patient 
information went into a specifically designed data form that 
included demographics, medical history, medication history, 
stroke severity, blood pressure, initial laboratory and neuro-
imaging results, the time of stroke onset, time of arrival, 
time of neuro-imaging, time of thrombolysis administration, 
in-hospital complications, mortality and discharge 
information. The definition of the time of stroke onset 
comprised the time when the patient or a bystander first 
noticed any neurological symptoms. For patients found with 
symptoms, or where symptoms became first noticed upon 
awaking, the stroke onset time definition encompassed the 




The statistical analyses incorporated the use of the 
Statistical Package for the Social Sciences (SPSS) (version 
19). The Student’s t-test and the Mann–Whitney U test 
compared parametric and non-parametric continuous 
variables, respectively, while the independent samples chi-
square test compared categorical variables. A multivariate 
analysis, using backward stepwise logistic regression, 
assessed the impact of a number of factors on the likelihood 
of the patients presenting within the treatment window 
(≤4.5 hours) versus late (>4.5 hours). Combining variables 
with a univariate P<0.10 into a multivariate backward 
stepwise logistic regression model assessed their predictive 
ability while controlling for the effects of other predictors in 
the model. The following independent variables initially 
tested in the univariate analyses included: patient age, 
gender, co-morbidities, previous history of stroke or TIA, the 
absence of witnesses at the stroke onset, whether an 
ambulance was immediately called at the onset, weekend 
admission, mode of hospital arrival, stroke severity (using 
the National Institutes of Health Stroke Scale and the 
Glasgow Coma Scale),
3
 and stroke symptoms at onset. A P 
value of <0.05 comprised the alpha level of significance in all 
of the analyses.  
 
Relevant human research ethics committees at each 
hospital approved the study protocol prior to 




Researchers completed a review of a total of 521 patients’ 
medical records; these represented 41.3% of all the AIS 
admissions to the five hospitals during the 12-month study 
period. Table 2 outlines the patient demographics. The 
results showed a mean age of 74 ±14 years, and a similar 
proportion of males and females. The age group over 80 




years characterised a substantial proportion (43.6%) of the 
patients who presented within the thrombolysis time 
window (≤4.5 h). Since the national guidelines considers the 
cut-off age at 80 years,
2 
the study currently considers this 
age as a relative contraindication to thrombolysis.  
 
Stroke Presentation  
 Patients arriving in time (≤4.5 h) 
Almost one-third of the AIS patients arrived within the 
required time frame (within the thrombolysis time window, 
≤4.5 h), and the remaining two thirds arrived passed the 
recommended time frame (beyond the thrombolysis time 
window, >4.5 h) (Figure 1). 
 
The majority of the patients admitted within the 
thrombolysis time window did not receive thrombolysis. 
The most commonly documented reasons for not using 
thrombolysis related to rapidly improving symptoms and 
minor symptoms (Table 3).  
 
The medical record of a considerable proportion of the 
patients (14.7%, similar to the proportion who actually 
received thrombolysis) contained no documented reason 
for exclusion. Five patients presented with other reasons for 
exclusion, including such factors as: clot not found upon 
neuro-imaging (two patients), enoxaparin therapy being 
used (low molecular weight heparin anticoagulant), relevant 
information missing from the medical history and 
inadequate thrombolysis work-up time. No patients were 
excluded for the following reasons: symptoms suggestive of 
subarachnoid haemorrhage, neuro-imaging showing 
haemorrhage, uncontrolled hypertension, recent 
myocardial infarction within the previous 30 days, head 
trauma or prior stroke within the previous three months or 
patient or family refusal of thrombolysis. 
 
 Late arrival of patients (>4.5h)  
Approximately half (51.4%) of the patients’ medical records 
contained a documented time of stroke onset. The median 
onset-to-arrival time for the patients arriving within 4.5 
hours showed significantly shorter times than those arriving 
late (88 min vs. 585 min, respectively, P<0.001). The median 
time from ambulance contact to arrival did not differ 
significantly between the patients arriving in time and those 
arriving late (55 min vs. 58 min, respectively, P>0.05). 
However the onset to ambulance contact time 
demonstrated significantly longer times in the patients 
arriving late (19 min vs. 386 min, P<0.001), suggesting that 
this factor may validate one reason for the delay. In a key 
side note, the data revealed that 81 (23%) of the patients in 
this group arrived via private vehicle and did not use the 
ambulance. 
Forty-four per cent (159/358) of the patients exhibited an 
unknown onset time; of these patients, 17% experienced 
stroke onset during their sleep and discovered the 
symptoms after awaking. One-fifth of the patients arrived 
late due to being discovered by another person finding the 
patient in a state that rendered them unable to seek help, 
and an additional 12% were found while unaware of their 
symptoms. Forty-two per cent of patients presenting late 
reported being alone at stroke-onset and 14% of these 
cases demonstrated altered consciousness at onset. 
 
The AIS patients (n=521) took the following actions when 
discovering their first symptoms: 50% called an ambulance, 
8.2% contacted their (general practitioner) GP, 6.2% went to 
the hospital, 5% contacted a relative, friend, neighbour or 
stranger, and 30.5% sought no help at all. 
 
Sixty-one per cent of the patients presenting late sought no 
medical attention immediately after symptom onset. Of 
those, 41% (146) of patients waited for their symptoms to 
improve, and 21 patients tried to ‘sleep off the symptoms’. 
Sixty-two (17%) of the patients contacted their GP after 
symptom onset rather than an ambulance. 
 
The medical record contained the stroke severity score on 
admission in 41.5% of AIS patients. However, this study 
failed to find a significant difference in the degree of stroke 
severity between the patients arriving in time versus those 
arriving late (P=0.45).  
 
The majority (70%) of the strokes occurred at a private 
home or a nursing home. Compared to the patients whose 
stroke occurred at a private home, patients with stroke 
onset at a nursing home exhibited a significantly shorter 
median onset-to-arrival time (227 minutes vs. 112 minutes, 
respectively, P=0.017).  
 
Factors associated with patients arriving late (>4.5 h) 
The univariate analyses identified nine independent 
variables as potential predictors of late arrival (Table 4). 
These variables provided the data for the multivariate 
analysis. The final model contained five independent 
variables, ‘patient alone at onset’, ‘patient waiting for 
symptoms to improve’, ‘confusion (accompanying symptom 
onset)’, ‘presence of facial droop/slurred speech at the 
onset of stroke’ and ‘immediately calling an ambulance at 
the onset of stroke’(Table 5). 
 
Among the three factors positively associated with late 
arrival to hospital (>4.5 h), ‘confusion (accompanying 
symptom onset)’ and ‘patient waiting for symptoms to 
improve’ proved to be stronger predictors of late arrival 




than ‘patient being alone at onset’. Regarding the factors 
negatively associated with late arrival (>4.5 h), ‘immediately 
calling an ambulance at the onset of stroke’ established 
itself as a stronger predictor, than the ‘presence of facial 
droop/slurred speech at the onset of stroke’. 
 
The model as a whole explained between 31.2% (Cox and 
Snell square) and 42.2% (Nagelkerke R squared) of the 
variance in patient arrival time and correctly classified 
76.4% of the cases (X
2
=109.3, P<0.001).  
 
Discussion 
In an attempt to identify and prioritise the key areas 
needing potential interventions and to increase 
thrombolysis utilisation and consequently decrease stroke 
disability, this study identified and quantified reasons as to 
why patients arriving at the hospital in time do not receive 
thrombolysis. Furthermore, this study identified the factors 
associated with late arrival of patients. A strength of the 
study encompasses including real-life stroke cases and 
recording which actions the patients and/or bystanders 
actually took at the onset of symptoms or the time of 
symptom discovery. This strength contrasts with earlier 
studies which focused on assessing hypothetical actions 
that patients may take at stroke onset. The study found that 
in addition to the patient being alone or confused at onset, 
failure of the patient to take appropriate action represented 
a significant factor leading to late patient arrival. 
 
For the patients arriving to hospital in time, minor and 
rapidly improving symptoms remain the primary reasons for 
not using thrombolysis. The guidelines
2-4
 recommend 
excluding patients with minor or rapidly improving 
symptoms because the risks outweigh the benefits of 
treatment. A study in Canada confirmed that the main 
reason for excluding patients who arrive within the time 
frame involved minor and rapidly improving symptoms.
16
 
However, the Canadian study also found that 32% of these 
patients either died or remained dependent at hospital 
discharge, and it questioned the appropriateness of 
excluding these patients from thrombolysis. Currently, no 
clear definition of ‘rapidly improving symptoms’ in any of 
the recognised guidelines (American, Australian or 
European)
2-4
 exists, and many cases are excluded from 
thrombolysis because of an improvement in the motor 
symptoms after the initial onset and despite incomplete 
resolution on admission. Future research could identify 





A considerable proportion of the patients arriving in time 
represented the age group of 80 and above. According to 
the Australian guidelines,
2
 age greater than 80 years 
remains a relative contraindication for thrombolysis. 
American guidelines, places an absolute contraindication on 
patients presenting between 3-4.5 hours.
9
 The European 
guidelines,
4
 recommend thrombolysis in certain patients 
over the age of 80, although the labeling of tPA (Alteplase®) 
fails to include this age group in the current European 
marketing of the product.
17
 This exclusion represents the 
previous limited evidence from randomised controlled trials 
(RCT) to show benefits from thrombolysis administration in 
this group of patients rather than related to a higher 
demonstrated risk of haemorrhagic complications.
18
 The 
recently reported IST-3 trial now provides evidence that 
thrombolysis is both safe and effective in patients over 80 
and most likely the international guidelines will undergo 




In our study, only a minority (14.7%) of the patients arriving 
in time actually received thrombolysis. This study describes 
the proportion to be lower than the proportions reported in 




 of patients 
arriving in time received thrombolysis. Also, an additional 
14.7% of the patients in our study who presented in time 
and with no documented contraindications failed to receive 
thrombolysis, which highlights the underutilisation of 
thrombolysis in potentially eligible patients. This deficit 
could be overcome by the development of decision-making 
tools to assist clinicians in the timely assessment of the risks 
and benefits of thrombolysis.  
 
The largest barrier to thrombolysis continues to be late 
patient presentation. Exclusion comprised approximately 
69% of the patients in the study for this reason; other 





However, it must be noted that the recent extension of the 
thrombolysis time window from 3 to 4.5 hours occurred 
prior to these studies and the majority of studies reported 
in the literature. All of the studies conducted to date, 
including the current one found that shortening the time 
from stroke onset to hospital arrival produced the single 




Patient reluctance to seek treatment still exists as the main 
factor leading to this delay.
20
 Our study found that ‘patient 
waiting for symptoms to improve’ stood out as an 
important predictor of late arrival and that ‘immediately 
contacting the ambulance’ predicted in-time arrival. 
Another discovery indicated that transportation to the 
hospital by an ambulance service caused only a small 
portion of the delay and no difference existed in the 
ambulance-contact-to-arrival times of the patients 
presenting in time and those presenting late. The data 




confirms the findings of other studies
20
 in which the 
ambulance service contributed minimally to the pre-
hospital delay.  
 
The presence of facial droop and/or slurred speech at 
stroke-onset significantly predicted arrival in time. This 
association may stem from these symptoms being 
somewhat alarming in contrast to other stroke symptoms, 
such as numbness or minor limb weakness. Similarly, 
another Australian study found that speech problems 
showed an association with earlier ambulance contact.
 21
 
The study also found that stroke severity failed to be 
associated with either in-time or late arrival, which may be 
explained by some patients with severe, unattended strokes 
having long delays before reaching a hospital.
21
 No 
significant association exists between any of the stroke risk 
factors and the time of presentation. Previous studies 
reported similar findings,
20
 although not for previous 
stroke/TIA. The studies found these factors associated with 
decreased pre-hospital delay, presumably because the 
patients had previous experience and education on how to 
respond appropriately. These findings provide evidence that 
targeted patient education reduces pre-hospital delay.  
 
Our study found that ‘the patient being alone at onset’ 
signifies a critical factor leading to delay. This finding 
appears in other studies.
20
 The majority of stroke attacks 
occurred while the patients resided at home, and 
approximately 30% of the patients reported living alone. 
Given that stroke symptoms can affect a patient’s ability to 
seek help, a significant number of patients can be expected 
to present late because of this factor. Moreover, the 
presence of confusion at onset of stroke symptoms 
indicates the most salient predictor of late arrival. This delay 
could be avoided by utilising currently available personal 
emergency communication services. These services provide 
patients with a water-proof pendant that can be attached to 
a necklace or a wristband and that can be easily activated 
by the patient at the onset of initial symptoms (even in the 
presence of mild confusion) to alert a dispatcher to alert an 
ambulance service promptly.  
 
A significant proportion of stroke patients presented with 
an unknown onset time for reasons that included onset 
during sleep, being unaware of symptoms, and an 
unattended onset of a stroke that significantly impacted the 
patient’s level of consciousness. In these cases, the onset 
time reverts back to the last time at which the patient was 
known to be well, and this assumption consequently leads 
to exclusion from thrombolysis because of late patient 
presentation. In some of our study patients, an advanced 
neuroimaging technique detected the presence of a 
salvageable penumbra (i.e., viable brain tissue that is under 
an ischaemic attack),
22
 and some of the patients presenting 
in time became excluded from thrombolysis due to failure 
to detect a salvageable penumbra. This technique is 
currently being investigated in some centres to confirm the 
presence of a salvageable penumbra in thrombolysis-
eligible patients prior to administering thrombolytics and 
clinical trials study select patients presenting beyond 4.5 





Public awareness campaigns that educate patients and their 
families on the appropriate actions continue to be needed. 
In this study, we found that an ambulance was contacted 
immediately after first discovery of symptoms in only 50% 
of the cases and that ‘immediately contacting an 
ambulance’ predicted arrival in-time for treatment. Several 
public awareness campaigns appear worldwide, the Brain 
Attack campaign in the US and the F.A.S.T campaign in 
Australia, for example.
11,12
 These campaigns aim to increase 
community knowledge of stroke, stroke risk factors, stroke 
warning signs and symptoms, and the importance of 
promptly contacting an emergency service.
25
 Further 
research needs to identify the reasons for the limited effect 
of these campaigns. It has been suggested that the message 
being delivered needs to be modified to include such items 
as “do not call a GP”, “seek help even if you think symptoms 
are minor”, “do not wait for symptoms to improve” and 
“drug treatment is only available for patients who seek help 
early”.
26
 However, these campaigns may fail to reach their 
target population, which consists of patients with elevated 
stroke risk and their families. Community pharmacists play 
an important role because they are in a position to identify 
patients at risk for stroke through specifically developed 
screening programs,
27
 reinforce key messages regarding the 
early recognition of stroke symptoms and the appropriate 





The limitations of this study include its retrospective design 
and our reliance on ICD-10 codes to identify the AIS 
patients. In addition, the data remains limited to the 
information documented in the medical records and 
ambulance transfer forms. In some cases, the research team 
relied on the physician’s interpretation of whether the 
symptoms rated minor or rapidly improving rather than on a 
validated stroke-specific tool due to the score failing to be 
documented (a significant finding in and of itself). Finally, 
only five metropolitan hospitals in a single state comprise 
the study population, necessitating caution when 
interpreting the findings of this study. Despite these 
limitations, this study provided important insights into why 




patients were excluded from thrombolysis in clinical 
practice and identified areas for possible interventions that 
may increase thrombolysis utilisation and consequently 
decrease patient disability from stroke.  
 
Conclusion 
In conclusion, minor and rapidly improving symptoms 
remain the major reasons for exclusion in the patients 
presenting within the thrombolysis time window, and a 
considerable proportion of the patients being older than 80 
years failed to meet inclusion criteria. Further research 
should consider identifying patients with improving 
symptoms who might benefit from thrombolysis. Among 
the patients who arrive late, however, a delay in seeking 
treatment exists as the major factor leading to late arrival, 
which emphasized the need for a more tailored and 
targeted public education campaign.   
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Table 1:  Hospital characteristics  
 
Characteristics Hospitals (N=5) 
TRC-1 TRC-2 DH-1 DH-2 DH-3 
Size (beds) 740 650 200 400 485 
Acute Stroke 
Unit  








population   





















Both I.V and I.A 
thrombolysis 
are utilised:  
- I.V <3 h from 
onset of stroke  
- I.A <6 h from 
stroke onset 
- mechanical 
clot retrieval is 





























presenting to the 
hospital within 
two hours of 
stroke onset to 




Note: DH-1 is 
located in the 
Catchment area 











March 2010, i.e. 














acute stroke team 
which allows 
hospital bypass, 
alerts triage and 
CT radiology, and 
rapidly assess the 
patient on arrival 
to the emergency 
department. 





































































TRC, tertiary referral centres; DH, district hospitals; SD, standard deviation; TIA, transient ischaemic attack; 
PVD, peripheral vascular disease. 
















Patients arrival interval 
≤4.5 h (%) >4.5 h (%) 
Age (years) mean ±SD  
range 
 
74.4 ±14  
(5-102) 
75.8 ±13  
(28-94) 
73.8 ±15  
(5-102) 
Age ≥65 (years)  
 
414 (79.5) 82.8 77.9 
Age >80 (years)  
 
207 (39.7) 43.6 38.0 
Female  
 
254 (48.8) 50.3 48.0 
Pre-morbid living status†    
          Patient lives alone 154 (29.9) 25.2 31.6 
          Patient lives in nursing home 53   (10.3) 10.4 10.1 
          Patient lives with family 
 
301 (58.4) 62.6 55.6 
Admitted via ambulance†  
 
404 (79.8) 86.8 76.7 
Presenting hospital    
          TRC-1 133  (25.5) 28.2 24.3 
          TRC-2 117  (22.5) 25.8 20.9 
          DH-1 94    (18.0) 13.5 20.1 
          DH-2 85    (16.3) 14.1 17.3 
          DH-3 
 
92    (17.7) 18.4 17.3 
Medical history    
         Hypertension 343  (65.8) 62.6 67.3 
         Hypercholesterolemia 239  (45.9) 47.2 45.3 
         Previous stroke/TIA  173 (33.2) 34.4 32.7 
         Atrial fibrillation 159  (30.5) 33.7 29.1 
         Tobacco use (current/past)  151 (29.0) 28.2 29.3 
         Ischemic heart disease 132  (25.3) 25.2 25.4 
         Diabetes  124  (23.8) 19.0 26.0 
         Cancer (current/past) 84    (16.1) 15.3 16.5 
         Dementia 51    (9.8) 12.9 8.4 
High Alcohol use (current/past) 36    (6.9) 8.0 6.4 
         PVD 31    (6.0) 6.1 5.9 




Table 3: The reasons for not using thrombolysis in the patients presenting in time, n=163 
 
Reason No. (%) 
Rapidly improving symptoms 46 (28.2) 
Minor symptoms 28 (17.2) 
Receiving an anticoagulant  
with an INR >1.5  
11 (6.7) 
Severe stroke 9   (5.5) 
No salvageable penumbra 6   (3.7) 
Severe co-morbidity 4   (2.5) 
Major Surgery (within 14 days) 2   (1.2) 
Gastrointestinal haemorrhage (within 
30 days) 
2   (1.2) 
History of ICH 1   (0.6) 
Seizure 1   (0.6) 
Other 5   (3.1) 
No documented reason 24 (14.7) 










































Table 4: Univariate analyses, showing the associations between variables and in-time/late arrival 
 







OR (95% CI) Univariate P  
Age, median (years) 78.6 77.0 1.01 (1.00-1.02) 0.155 
Age ≥65 82.8 77.9 0.73 (0.45-1.18) 0.200 
Age >80 43.6 38.0  0.79 (0.54-1.15) 0.228 
Female Gender 50.3 48 1.10 (0.76-1.58) 0.632 
Australian born 71.4 74.6 1.18 (0.75-1.85) 0.487 
English speaking 92.4 90.4 0.77 (0.39-1.54) 0.457 
Hypertension 62.6 67.3 1.23 (0.83-1.82) 0.290 
Ischemic heart disease  25.2 25.4 1.01 (0.66- 1.56) 0.948 
Diabetes  19.0 26.0 1.49 (0.94-2.38) 0.084 
Atrial fibrillation  33.7 29.1 0.81 (0.54-1.19) 0.281 
Hypercholesterolemia  47.2 45.3 0.93 (0.64-1.33) 0.673 
PVD  6.1 5.9 0.95 (0.44-2.08) 0.904 
Cancer  15.3 16.5 1.09 (0.65-1.82) 0.742 
Dementia  12.9 8.4 0.62 (0.34-1.11) 0.109 
Previous stroke/ TIA  34.4 32.7 0.93 (0.63-1.37) 0.707 
Tobacco use (current/past) 28.2 29.3 1.05 (0.70-1.59) 0.796 
High Alcohol use 8.0 6.4 0.79 (0.39-1.61) 0.518 
Pre-morbid mRS ≤1  89.8 89.9 1.01 (0.30-3.33) 0.992 
Pre-morbid independence in ADLs  80.3 86.3 1.56 (0.93-2.56) 0.085 
Alone at onset 34.8 58.8 2.63 (1.72-4.17) 0.000* 
Action taken when symptoms were 
discovered: immediate call for 
ambulance   
66.9 34.9 0.27 (0.18-0.39) 0.000* 
Action taken when symptoms were 
discovered: went to hospital   
7.4 4.7 0.63 (0.29-1.35) 0.228 
Patient waited for symptoms to 
improve  
16.7 62.9 8.33 (5.00-14.29) 0.000* 
Pre-hospital consultation  3.7 18.4 5.88 (2.5-14.29) 0.000* 
Weekend admission  30.1 25.7 1.25 (0.79-1.96) 0.341 
Mode of arrival by Ambulance  86.8 76.7 0.5 (0.30-0.84) 0.008* 
Admission: NIHSS ≤22† 95.2 100 0.78 (0.68-0.91) 0.461 
Admission: GCS ≤9‡ 5 3.25 0.62 (0.25-1.59) 0.314 
Facial droop, drooling, slurred speech  73.6 52.5 0.40 (0.26-0.60) 0.000* 
Limb weakness  63.2 52.8 0.65 (0.44-0.95) 0.027* 
Confusion  1.7 13.6 4.17 (2.04-8.33) 0.000* 
Unsteady gait   8 23.5 3.57 (1.92-6.67) 0.000* 
Fall/ collapse at onset 34.4 29.6 0.81 (0.54-1.19) 0.278 
PVD, peripheral vascular disease; TIA, transient ischaemic attack; mRS, modified Rankin scale; ADL, activities of 
daily living; NIHSS, National Institutes of Health Stroke Scale; GSC, Glasgow Coma Scale. 
† data available for only 53 patients 
‡ data available for 494 patients 













Table 5: Multivariate analysis, showing the factors independently predicting late patient arrival (>4.5 h)  
 




Patient alone at onset 0.91 2.50 1.35-4.55 
Patient waited for symptoms to improve 1.52 4.55 2.22-9.09 
Confusion at onset 1.80 5.88  2.17-16.67 
Facial droop/ slurred speech at onset -0.99 0.37 0.20-0.70 
Ambulance immediately called at onset -1.34 0.26 0.13-0.51 





































68.7% Late arrival 
> 4.5 h (n=358)  
Not Thrombolysed 
31.3 % In-time arrival 
≤4.5 h (n=163) 
